Thalidomide has a therapeutic effect on interstitial lung fibrosis: Evidence from in vitro and in vivo studies

Clinical and Experimental Immunology

Volumn 157, Issue 2, 2009, Pages 310-315

  Zhao, L ^a   Xiao, K ^a   Wang, H ^a   Wang, Z ^a   Sun, L ^a   Zhang, F ^a   Zhang, X ^a   Tang, F ^a   He, W ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Interstitial lung fibrosis; Thalidomide

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; HYDROXYPROLINE; MESSENGER RNA; PROCOLLAGEN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROBLAST; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACTINS; ANIMALS; BLEOMYCIN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN TYPE III; FEMALE; FIBROBLASTS; HUMANS; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67650689308     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03962.x     Document Type: Article

References (22)

1. Renzoni EA. Interstitial lung disease in systemic sclerosis. Monaldi Arch Chest Dis 2007 67 : 217 28.
2. Fujisawa T, Suda T, Nakamura Y et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005 32 : 58 64. (Pubitemid 40092592)
3. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006 12 : 346 53.
4. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006 54 : 3962 70.
5. Clements PJ, Roth MD, Elashoff R et al. Scleroderma Lung Study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007 66 : 1641 7.
6. Khanna D, Yan X, Tashkin DP et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007 56 : 1676 84.
7. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991 138 : 1257 65.
8. Phan SH, Zhang K, Zhang HY et al. The myofibroblast as an inflammatory cell in pulmonary fibrosis. Curr Top Pathol 1999 93 : 173 82.
9. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002 122 (6 Suppl 286S 9S.
10. Gauldie J, Sime PJ, Xing Z et al. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr Top Pathol 1999 93 : 35 45.
11. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005 353 : 2229 42.
12. Ihn H. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008 49 : 103 13.
13. Lv P, Paul SC, Xiao Y et al. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators Inflamm 2006 2006 : 93253.
14. Tabata C, Tabata R, Kadokawa Y et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007 179 : 708 14.
15. Ye Q, Chen B, Tong Z et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006 28 : 824 31.
16. Malmstrom J, Westergren-Thorsson G, Marko-Varga G. A proteomic approach to mimic fibrosis disease evolvement by an in vitro cell line. Electrophoresis 2001 22 : 1776 84.
17. Yamamoto T, Takagawa S, Katayama I et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999 112 : 456 62.
18. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V. Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002 102 : 77 83. (Pubitemid 34095227)
19. Selman M, Thannickal VJ, Pardo A et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004 64 : 405 30.
20. White ES, Lazar MH, Thannickal VJ. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003 201 : 343 54.
21. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 1999 21 : 658 65.
22. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000 292 : 535 41.